Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
146. Alves JD, Kumar S, Isenberg DA. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 2003; 42: 893—899.
147. Reichlin M, Fesmire J, Quintero-Del-Rio AI, et al Autoantibodies to lipoprotein lipase and dislipidemia in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2957—2963.
148. Romero FI, Atsumi T, Tinahones FJ, et al. Autoantibodies against malodialdehyde-modified ipoprotein(a) in antiphospholipid syndrome. Arthritis Rheum 1999; 42: 2606—2611.
149. Ames PRJ. Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: a unifying "membrane stress syndrome" hypothesis. Lupus 1994; 3: 371—377.
150. Violi F, Micheletta F, Iuliano L. Oxidant stress in SLE patients: relationship to atherosclerosis. In Atherosclerosis and autoimmunity. Ed Y. Shoenfeld, D. Harrats and G. Wick. Elseiver. 2001; 273—278.
151. Ames PRL, Alves J, Murat L, et al. Oxi-dative stress in systemic lupus erythematosus and allied conditions with vascular involvment. Rheumatology (Oxford) 1999; 38: 529—534.
152. Ferro D, Pittoni V, Quintarelli C, et al. Coexistence of antiphospholi[id antibodies and endothelial perturbations in systemic lupus ery-thematosus with ongoing prothrombotic state. Circulation 1997; 95: 1425—1432.
153. Iuliano L, Practico D, Ferro D, et al. Enhanced lipid peroxidation in patients positive for aPL. Blood 1997; 90: 3931—3995.
154. Ames PRJ, Nourooz-Zadech J, Tomasino C, et al. "Oxidative stress" in primary antiphos-
pholipid syndrome. Thrombosis Haemostasis 1998; 79: 447—449.
155. Ames PR, Alves J, Murat I, Isenberg DA. Nourooz-Zadeh J. Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology (Oxford) Jun 1999; 38 (6): 529—34.
156. Practico D, Ferro D, Iuliano L, et al. Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation. Blood 1999; 93: 3401—3407.
157. Martinuzzo ME, Forastiero RR, Kordich L, Carreras LO. Increased lipid peroxidation correlates with platelet activation but not with marker of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies. Br JHaematol 2001; 114: 845—851.
158. Ames PRJ, Tommasino C, Alves J, et al. Antioxidant susceptibility of pathogenic pathway in subjects with antiphospholipid antibodies: a pilot study. Lupus 2000; 9: 688—659.
159. Durrington PN, Mackness B, Maskness NI. Paraoxanase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 473—480.
160. Lambert M, Boullier A, Hachulla E, et al. Paraoxonasa activity is dramatically decreased in patients positive for anticardiolipin antibodies. Lupus 2000; 9: 299—300.
161. Alves JD, Ames PJR, Donohue S, et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythe-matosus and primary antiphospholipid syndrome. Arthritis Rheum, 2002; 46: 2686—2694.
162. Lambert M, Helbecque N, Martin F, et al. Evidence of paraoxanase polymorphism (Gln192 Arg) in patients with antiphospholipid syndrome. ACR 66th Annual Scientific Meeting October 25— 29, 2002; 539 (abst).
163. Alves JD, Mason L, Ames PRL, et al. Anticardiolipin antibodies are associated wirh decreased plasma nitric oxide and paraoxanase activity in a murine model of antiphospholipid syndrome. ACR/ARHP Annual Scientific Meeting October 24—28, 2003; 334 (abst).
164. ReiserH, StadeckerMJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996; 335: 1369—1377.
SHS-OOO4.qxd 21.11.2006 16:56 Page З3З6
36
Насонов Е.Л. Антифосфолипидный синдром.
-е-
165. Kalled SL, Cutler AH, Datta SK, Thomas DW. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 1998; 160: 2158—2165.
166. Huang W, Sinha J, Newman J, et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 2002; 46: 1554—1562.
167. Kato K, Santana-Sahagun E, Rassenti LZ, et al. The soluble CD40 ligand (sCD154) in systemic lupus erythematosus J Clin Invest 1999; 104: 974—955.
168. Aringer M, Smolen JS. Complex cytokine effect in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther 2003; 5: 172—177.
169. Samsonov MU, Tilz GP, Nasonov E, Egorova O, Balabanova RM, Nassonov, Wachter H, Fuchs D. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1995; 4: 29—32.
170. Бородин АГ, Баранов АА, Клюквина НГ, Абайтова НЕ, Насонов ЕЛ. Клинико-тогене-тическое значение фактора некроза опухоли-альфа при системной красной волчанке. Терапевт. архив, 2002; 5: 32—35.
171. Maury CP, Teppo AM. Tumor necrosis factor in serum of patients with systemic lupus ery-thematosus. Arthritis Rheum 1989; 32: 146—150.
